Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


10.1371/journal.pone.0237831

http://scihub22266oqcxt.onion/10.1371/journal.pone.0237831
suck pdf from google scholar
32817707!7440633!32817707
unlimited free pdf from europmc32817707    free
PDF from PMC    free
html from PMC    free

suck abstract from ncbi


Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534

Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
pmid32817707      PLoS+One 2020 ; 15 (8): e0237831
Nephropedia Template TP

gab.com Text

Twit Text FOAVip

Twit Text #

English Wikipedia


  • Tocilizumab and steroid treatment in patients with COVID-19 pneumonia #MMPMID32817707
  • Mikulska M; Nicolini LA; Signori A; Di Biagio A; Sepulcri C; Russo C; Dettori S; Berruti M; Sormani MP; Giacobbe DR; Vena A; De Maria A; Dentone C; Taramasso L; Mirabella M; Magnasco L; Mora S; Delfino E; Toscanini F; Balletto E; Alessandrini AI; Baldi F; Briano F; Camera M; Dodi F; Ferrazin A; Labate L; Mazzarello G; Pincino R; Portunato F; Tutino S; Barisione E; Bruzzone B; Orsi A; Schenone E; Rosseti N; Sasso E; Da Rin G; Pelosi P; Beltramini S; Giacomini M; Icardi G; Gratarola A; Bassetti M
  • PLoS One 2020[]; 15 (8): e0237831 PMID32817707show ga
  • INTRODUCTION: Coronavirus disease 2019 (COVID-19) can lead to respiratory failure due to severe immune response. Treatment targeting this immune response might be beneficial but there is limited evidence on its efficacy. The aim of this study was to determine if early treatment of patients with COVID-19 pneumonia with tocilizumab and/or steroids was associated with better outcome. METHODS: This observational single-center study included patients with COVID-19 pneumonia who were not intubated and received either standard of care (SOC, controls) or SOC plus early (within 3 days from hospital admission) anti-inflammatory treatment. SOC consisted of hydroxychloroquine 400mg bid plus, in those admitted before March 24th, also darunavir/ritonavir. Anti-inflammatory treatment consisted of either tocilizumab (8mg/kg intravenously or 162mg subcutaneously) or methylprednisolone 1 mg/kg for 5 days or both. Failure was defined as intubation or death, and the endpoints were failure-free survival (primary endpoint) and overall survival (secondary) at day 30. Difference between the groups was estimated as Hazard Ratio by a propensity score weighted Cox regression analysis (HROW). RESULTS: Overall, 196 adults were included in the analyses. They were mainly male (67.4%), with comorbidities (78.1%) and severe COVID-19 pneumonia (83.7%). Median age was 67.9 years (range, 30-100) and median PaO2/FiO2 200 mmHg (IQR 133-289). Among them, 130 received early anti-inflammatory treatment with: tocilizumab (n = 29, 22.3%), methylprednisolone (n = 45, 34.6%), or both (n = 56, 43.1%). The adjusted failure-free survival among tocilizumab/methylprednisolone/SOC treated patients vs. SOC was 80.8% (95%CI, 72.8-86.7) vs. 64.1% (95%CI, 51.3-74.0), HROW 0.48, 95%CI, 0.23-0.99; p = 0.049. The overall survival among tocilizumab/methylprednisolone/SOC patients vs. SOC was 85.9% (95%CI, 80.7-92.6) vs. 71.9% (95%CI, 46-73), HROW 0.41, 95%CI: 0.19-0.89, p = 0.025. CONCLUSION: Early adjunctive treatment with tocilizumab, methylprednisolone or both may improve outcomes in non-intubated patients with COVID-19 pneumonia.
  • |Adult[MESH]
  • |Aged[MESH]
  • |Aged, 80 and over[MESH]
  • |Anti-Inflammatory Agents/administration & dosage/*therapeutic use[MESH]
  • |Antibodies, Monoclonal, Humanized/administration & dosage/*therapeutic use[MESH]
  • |Antimalarials/administration & dosage/therapeutic use[MESH]
  • |Betacoronavirus[MESH]
  • |COVID-19[MESH]
  • |COVID-19 Drug Treatment[MESH]
  • |Coronavirus Infections/*drug therapy/virology[MESH]
  • |Darunavir/therapeutic use[MESH]
  • |Female[MESH]
  • |Follow-Up Studies[MESH]
  • |HIV Protease Inhibitors/therapeutic use[MESH]
  • |Humans[MESH]
  • |Hydroxychloroquine/administration & dosage/therapeutic use[MESH]
  • |Male[MESH]
  • |Methylprednisolone/administration & dosage/*therapeutic use[MESH]
  • |Middle Aged[MESH]
  • |Pandemics[MESH]
  • |Pneumonia, Viral/*drug therapy/virology[MESH]
  • |Ritonavir/therapeutic use[MESH]
  • |SARS-CoV-2[MESH]


  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    Linkout box